Replies to post #7634 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Market_Fest4]

RB, you are correct. I assumed COR had made the submission already but didn't feel the need to PR until approval.

If they haven't submitted the IND by the end of this week, I would really like to know why?

The only other possibility I can conjure is that they are in the final stages of a BP deal that has the BP submitting the IND. Since the BP would likely want to do deeper testing than COR, perhaps that's the explanation?
MF4

[neuroinv]

<<Cortex has been sitting in a dead calm for sixteen months>>

Are you talking about Cortex Pharmaceuticals, the CNS company? What dead calm? I have seen quite the opposite, a very small company that has had to hit overdrive for much of the past sixteen months in order to assess and then respond to the histopathology issue that dogged the company. A few months before Gary Rogers retired from Cortex, I needed to ask him a minor question, so I left a message on voicemail on a weekend, figuring on a response sometime the following week. He called me on Saturday afternoon, from Cortex, where he was working. When I told him this surprised me, he said that everyone was working overtime because they were juggling extra tasks (especially when Mansbach left). Speaking of Mansbach, without a Chief Medical Officer focused on clinical trials, they have had to develop an ADHD protocol without anyone whose primary role is writing protocols. And hiring a new CMO just became a lot easier with the FDA's dose-lifting...but not in time to do the ADHD trial protocol--which needs to be done right if they want the Psychiatric Division to simply allow it to become active. When I inquired as to how it was getting done, I was told that Gary Tollefson, who has a lot of experience with clinical trial planning, was helping out--but the fact he is CEO of his own company means his contributions as a member of Cortex's BOD are anything but fulltime.

NeuroInvestment